Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immunooncology (IO) agents who do not meet eligibility criteria for clinical trials

Chun Loo Gan¹, Shaan Dudani¹, J. Connor Wells¹, Ziad Bakouny², Nazli Dizman³, Sumanta K Pal³, Bernadett Szabados⁴, Lori A. Wood⁵, Christian Kollmannsberger⁶, Neeraj Agarwal⁷, Frede Donskov⁸, Naveen S. Basappa⁹, Georg A. Bjarnason¹⁰, Francis Parnis¹¹, Camillo Porta¹², Ian D Davis¹³, Ulka N Vaishampayan¹⁴, Ravindran Kanesvaran¹⁵, Toni K. Choueiri², Daniel YC Heng^{1*}

¹Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada, ²Dana-Farber Cancer Institute, London, UK, ⁵Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada, ⁶British Columbia Cancer Agency, Vancouver, British ¹Tom Baker Cancer Centre, University of London, UK, ⁵Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada, ⁶British Columbia Cancer Agency, Vancouver, British ¹Tom Baker Cancer Centre, Halifax, Nova Scotia, Canada, ⁶British Columbia Cancer Agency, Vancouver, British ¹Tom Baker Cancer Centre, Halifax, Nova Scotia, Canada, ⁶British Columbia Cancer Agency, Vancouver, British ¹Tom Baker Cancer Centre, Halifax, Nova Scotia, Canada, ⁶British Columbia Cancer Agency, Vancouver, British ¹Tom Baker Cancer Centre, Halifax, Nova Scotia, Canada, ⁶British Columbia Cancer Agency, Vancouver, British ¹Tom Baker Cancer Centre, Halifax, Nova Scotia, Canada, ⁶British Columbia Cancer Agency, Vancouver, British ¹Tom Baker Cancer Centre, Halifax, Nova Scotia, Canada, ⁶British Columbia Cancer Agency, Vancouver, British ¹Tom Baker Cancer Centre, Halifax, Nova Scotia, Canada, ⁶British Columbia Cancer Agency, Vancouver, British ¹Tom Baker Cancer Centre, Halifax, Nova Scotia, Canada, ⁶British Columbia Cancer Agency, Vancouver, British ¹Tom Baker Cancer Centre, Halifax, Nova Scotia, Canada, ⁶British ¹Tom Baker Centre, Canada, ⁶British ¹Tom Baker Centre, Halifax, Nova Scotia, Canada, ⁶British ¹Tom Baker Centre, Canada, ⁶British ¹Tom Baker ¹Tom Columbia, Canada, ⁷University of Utah Huntsman Cancer Institute, Salt Lake City, UT, ⁸Aarhus University Adelaide, Australia, ¹²IRCCS San Matteo University of Utah Huntsman Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Utah Huntsman Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Utah Huntsman Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Utah Huntsman Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Alberta, Edmonton, AB, Canada, ¹⁰Sunnybrook Odette Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Alberta, Edmonton, AB, Canada, ¹⁰Sunnybrook Odette Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Alberta, Edmonton, AB, Canada, ¹⁰Sunnybrook Odette Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Alberta, Edmonton, AB, Canada, ¹⁰Sunnybrook Odette Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Alberta, Edmonton, AB, Canada, ¹⁰Sunnybrook Odette Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Alberta, Edmonton, AB, Canada, ¹⁰Sunnybrook Odette Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Alberta, Edmonton, AB, Canada, ¹⁰Sunnybrook Odette Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University of Alberta, Edmonton, AB, Canada, ¹⁰Sunnybrook Odette Cancer Centre, Adelaide, Australia, ¹⁴IRCCS San Matteo University, ¹⁴IRCCS San Matteo University, ¹⁵IRCCS San Matteo Uni ¹⁴Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, ¹⁵Department of Medical Oncology, National Cancer Centre Singapore, Singapore

Background

- IO combination therapies [including IOIO and IO/vascular endotheli growth factor inhibitor (IOVE) combinations] in mRCC have been approved based on registration clinical trials that have strict eligibility criteria.
- In the IO era, the clinical outcomes of trial-ineligible patients who we treated with first-line IOIO or IOVE combinations are unknown.

Methods

- Using the International mRCC Database Consortium (IMDC) databa patients with mRCC patients treated with first-line IOIO or IOVE wer identified and retrospectively deemed ineligible for clinical trials (according to commonly used inclusion/exclusion criteria in IO trials Table 2).
- Primary outcomes of interest were:
- Overall response rate (ORR)
- Time to treatment failure (TTF)
- Time to next treatment (TTNT)
- Overall survival (OS)
- Multivariable Cox regression models were performed to adjust for imbalances in IMDC risk factors.


Results

- Overall, 26% (155/592) of patients were deemed ineligible for clinical trials. Baseline characteristics are reported in Table 1.
- Overall survival by trial eligibility is depicted in Figure 1. Other clinical outcomes are shown in Table 3.
- The most common toxicities leading to treatment discontinuation were hepatitis, colitis, and nephritis.
- The treatment discontinuation rate due to toxicities in the ineligible versus eligible patients was 33% vs. 37% (p=0.42), respectively.

Table 1: Baseline characteristics and IMDC risk factors

al	Baseline characteristics	Trial-ineligible (N = 155)	Trial-eligible (N = 437)	P-value	
ty	Median age (yrs)	62	63	0.24	
	Male	63% (98/155)	73% (318/437)	0.03	
	Non-clear-cell histology	40% (50/125)	2% (7/310)	<0.01	
	Sarcomatoid histology	25% (29/115)	20% (63/314)	0.25	
ere	Prior nephrectomy	66% (102/155)	75% (326/437)	0.04	
	Brain metastases	19% (29/153)	0% (0/408)	<0.01	
	ΙΟΙΟ	63% (97/155)	57% (247/437)	0.19	
	IOVE	37% (58/155)	43% (190/437)		
	Patients who had second line therapy	33% (50/155)	34% (148/437)	0.72	
	IMDC risk groups				
ase, re	Favorable	11% (15/138)	19% (74/385)	<0.01	
	Intermediate	47% (65/138)	65% (251/385)		
	Poor	42% (58/138)	16% (60/385)		
	IMDC risk factors				
"	KPS < 80%	20% (31/152)	5% (22/398)	<0.01	
	Diagnosis to therapy < 1 yr	73% (113/154)	66% (285/434)	0.08	
	Calcium > ULN	28% (37/132)	11% (40/378)	< 0.01	
	Hemoglobin < LLN	64% (96/150)	41% (169/414)	< 0.01	
	Neutrophils > ULN	19% (27/142)	10% (38/401)	0.03	
	Platelet > ULN	22% (32/148)	10% (39/412)	< 0.01	
	IOIO = Immuno-oncology agent combinations; IOVE = IO + vascular endothelial growth factor receptor				
	inhibitor: $KPS = Karnofsky performance status: I I N = lower limit of normal: UI N = upper limit of normal$				

Figure 1: Overall survival of trial-ineligible vs. eligible patients



 \mathcal{L}

ELIGIBLE	No. of Patients 155	Median OS (95% CI) mon 25.3 (17.4 - NR)	P < 0.0
IGIBLE	437	44.4 (34.3 – 54.8)	
or IMDC criteria):	1.49 (95% CI 1.05-2.14)		

Table 2: Number of patients excluded due to each exclusion criteria

Exclusion parameter†	Number of patients excluded due to this parameter/patients with available data %*(n/n)				
No clear-cell component in histology	34% (53/155)				
Hemoglobin < 9.0 g/dL	28% (44/155)				
eGFR < 40 mL/minute	19% (30/155)				
Brain metastases	19% (29/155)				
KPS < 70%	14% (21/155)				
Platelet < $100 \times 10^{3} / \mu L$	3% (4/155)				
Neutrophil count < 1500/µL	0% (0/155)				
eGFR = estimated glomerular filtration rate, KPS = Karnofsky performance status †181 exclusion criteria met in 155 patients *Total > 100% because patients may have had multiple exclusion parameters					

Table 3: Clinical outcomes of trial-ineligible vs. eligible patients

Clinical outcome	Trial-ineligible (N = 155)	Trial-eligible (N = 437)	P-value		
Response					
ORR	34% (42/124)	46% (164/358)	0.02		
Best response					
CR	4% (5/124)	4% (14/358)			
PR	30% (37/124)	42% (150/358)			
SD	40% (49/124)	34% (120/358)			
PD	26% (33/124)	20% (73/358)			
Median TTF (mon) (95% CI)	4.2 (2.7-6.7)	9.7 (7.79-11.3)	<0.01		
Median TTNT (mon) (95% CI)	13.2 (7.9-16.6)	19.7 (17.5-24.3)	<0.01		
CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; ORR= overall response rate CI = confidence interval: TTE = time to treatment failure: TTNT = time to next					

treatment

Conclusions

- warranted.



• The number of patients that are ineligible for clinical trials is substantial and their outcomes are inferior compared to trial-eligible patients.

• These data may guide patient counselling and inform real-world practice.

• Specific trials addressing the unmet needs of protocol-ineligible patients are

www.IMDConline.com